바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.69 No.2
Citation Share

Treatment Outcomes and Prognostic Factors in Patients with Multidrug-Resistant Tuberculosis in Korean Private Hospitals

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.69 no.2, pp.95-102























... (2010). Treatment Outcomes and Prognostic Factors in Patients with Multidrug-Resistant Tuberculosis in Korean Private Hospitals. Tuberculosis & Respiratory Diseases, 69(2), 95-102.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: The increasing rate of drug-resistant tuberculosis (TB) is a threat to the public health and TB control. In Korea, about 75∼80% of TB patients are treated in private hospitals and the rate has been continuously increasing since 2000. Methods: On a retrospective basis, we enrolled 170 newly diagnosed with or retreated for multidrug-resistant TB (MDR-TB) in 2004 from 21 private hospitals. We extracted the following demographics and treatment history from patient medical records: initial treatment outcomes, cumulative survival rates, treatment outcomes, and prognostic factors. Results: Of the 170 patients, the majority were male (64.1%), the mean age was 44.5 years old, and mean body- mass-index was 20.2 kg/m2. None of the patients tested positive for HIV. Eleven (6.5%) were confirmed to have extensively drug-resistant TB (XDR-TB) at treatment initiation. Treatment success rates were not different between XDR-TB (36.4%, 4/11) and non-XDR MDR-TB (51.6%, 82/159). Default rate was high, 21.8% (37/170). Far advanced disease on X-ray was a significant negative predictor of treatment success; advanced disease and low BMI were risk factors for all-cause mortality. Conclusion: In private hospitals in Korea, the proportion of XDR-TB in MDR-TB was comparable to previous data. The treatment success rate of MDR-/XDR-TB remains poor and the failure rate was quite high. Adequate TB control policies should be strengthened to prevent the further development and spread of MDR-/XDR-TB in Korea.

keywords
Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Korea, Hospitals, Private

Reference

1.

1. Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E,et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001∼2005. Tuberc Respir Dis 2008;64:187-93.

2.

2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva: World Health Organization; 2008.

3.

3. Caminero JA; World Health Organization; American Thoracic Society; British Thoracic Society. Treatment of multidrug-resistant tuberculosis: evidence and controversies.Int J Tuberc Lung Dis 2006;10:829-37.

4.

4. Korea Center for Disease Control and Prevention,Korean Institute of Tuberculosis. Annual report on the notified tuberculosis patients in Korea. Seoul: Korea Center for Disease Control and Prevention; 2005.

5.

5. Koh WJ, Kwon OJ, Kim CH, Ahn YM, Lim SY, Yun JW, et al. Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis at a private general hospital. Tuberc Respir Dis 2003;55:154-64.

6.

6. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH,et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82.

7.

7. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006;81:430-2.

8.

8. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language:treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-5.

9.

9. Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R,Facchini A, Guenther G, et al. MDR-TB and XDR-TB:drug resistance and treatment outcomes. Eur Respir J 2009;34:778-9.

10.

10. Park SK, Lee CM, Heu JP, Song SD. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2002;6:143-9.

11.

11. Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Resectional surgery combined with chemotherapy remains the treatment of choice for multidrugresistant tuberculosis. J Thorac Cardiovasc Surg 2004;128:523-8.

12.

12. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-5.

13.

13. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502.

14.

14. Rivers EC, Mancera RL. New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 2008;15:1956-67.

15.

15. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC 207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.

16.

16. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-91.

17.

17. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD,et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58:701-4.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy